Company: LGNZZ
Filing Date: 2025-02-25
Form Type: 8-K
Source: 0000886163-25-000003
Chunk: 2

Company: LIGAND PHARMACEUTICALS INC
Filing Date: 2025-02-25
Form: 8-K
Item: Item 9.01
Chunk 2
---
Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

  Exhibit No.      Description                             
         99.1      Press release dated February 25, 2025.  
 ───────────────────────────────────────────────────────────

Forward-Looking Statements

This report contains forward-looking statements, as defined in Section 21E of the Securities Exchange Act of 1934, as amended, that involve a number of risks and uncertainties and reflect Ligand’s judgment as of the date of this report. Although our forward-looking statements reflect the good faith judgment of our management, these statements can only be based on facts and factors currently known by us. Consequently, these forward-looking

statements are inherently subject to risks and uncertainties, and actual results and outcomes may differ materially from results and outcomes discussed in the forward-looking statements.

All statements contained herein, other than statements of historical fact, could be deemed to be forward-looking statements. In some instances, forward-looking statements can be identified by the use of forward-looking words such as “believes,” “expects,” “may,” “will,” “plan,” “intends,” “estimates,” “would,” “continue,” “seeks,” “pro forma,” or “anticipates,” or other similar words (including their use in the negative), or by discussions of future matters such as those related to our future results of operations and financial position; Ligand’s future royalty payments due under the Agreement; product development and product regulatory filings and approvals, and the timing thereof, including the trial and regulatory success of Castle Creek’s upcoming Phase 3 trial of D-Fi for patients with DEB; the potential high patient impact, and revenue potential, of D-Fi; Ligand may not receive expected revenue under this Agreement or others; Ligand or its partners may not be able to protect their intellectual property, and patents covering certain products and technologies may be challenged or invalidated which could expose Ligand to significant liabilities and have a material adverse effect on the company; as well as other statements that are not historical in nature. You should be aware that failure to meet expectations with regard to any of the foregoing matters could negatively affect our results of operations, financial condition and the trading price of our stock.

The cautionary statements made in this report are intended to be applicable to all related forward-looking statements wherever they may appear in this report. We urge you not to place undue reliance on these forward-looking statements, which reflect our good-faith beliefs (or those of indicated third parties) and